Jayne Lawrence
`
`PERSONAL DETAILS
`
`Full Name:
`Address:
`
`M Jayne Lawrence
`Royal Pharmaceutical Society & Institute of Pharmaceutical Science
`1 Lambeth High Street
`Franklin Wilkins Building
`London SE1 7JN
`150 Stamford Street
`London SE1 9NH
`
`EDUCATION AND AWARDS
`
`Name of Institution
`Royal Pharmaceutical Society
`(RPS)
`Academy of Pharmaceutical
`Sciences (APS)
`Academy of Pharmaceutical
`Sciences (APS)
`King’s College London (KCL)
`
`Dates
`2013
`
`2012
`
`2012
`
`Qualification/Award
`Faculty Fellow of the Royal Pharmaceutical
`Society (FFRPS)
`Eminent Fellow of the Academy of
`Pharmaceutical Sciences (EFAPS)
`Chair of 3rd APS UKPharmSci Conference
`
`2012
`
`Graduate School Supervisory Excellence
`Award
`Innovative Teaching Award - Finalist
`Innovative Teacher of the Year Award
`Registrant (Registration number 2027502)
`Fellow (Membership number 74865)
`Fellowship of the Royal Pharmaceutical
`Society (FRPharmS) – for Distinction in the
`Science of Pharmacy
`1985 - 1988 (part-time) Associate of King’s College (AKC) Distinction
`1982 - 2010
`Membership of the Royal Pharmaceutical
`Society of Great Britain (MRPharmS)
`1982 - 1984 (full time) PhD Pharmacy (awarded 1985)
`1978 - 1981 (full-time) BSc (Hons) Pharmacy First Class
`
`2011
`Times Higher Awards
`2011
`King’s College London
`General Pharmaceutical Council2010
`Royal Pharmaceutical Society
`2010
`Royal Pharmaceutical
`2009
`Society of Great Britain
`
`King’s College London
`Royal Pharmaceutical
`Society of Great Britain
`Manchester University
`Liverpool Polytechnic
`
`PREVIOUS APPOINTMENTS
`
`2007 - to date
`
`2003 - to date
`2002 - to date
`2000 - to date
`2000 - 2003
`1997 - 1999
`1984 - 1997
`1981 - 1982
`
`Chief Scientist, Royal Pharmaceutical Society (50% secondment from
`KCL) and Head of the RPS’s Science Team
`Professor in Biophysical Pharmaceutics, KCL
`Head of the Pharmaceutical Biophysics Group, KCL
`Visiting Professor, Chulalongkorn University, Bangkok, Thailand
`Reader in Drug Delivery, KCL
`Senior Lecturer in Pharmacy, KCL
`Lecturer in Pharmacy, KCL
`Pre-registration Pharmacist
`Clitherow Chemists, Liverpool)
`
`(Richardson-Vicks, Skelmesdale and
`
`NB 1/93 - 3/93 & 9/93 - 12/93; 6 months (total) sabbatical leave granted by Pharmacy Department, spent working
`in the Inhalation Research Group, Respiratory Product Development Section of Glaxo Group Research (now
`GlaxoSmithKline), Ware.
`
`SCIENTIFIC LEADERSHIP
`
`I have demonstrated scientific leadership in a number of ways.
`
`level, within
`For example I have considerable committee experience at National and International
`pharmacy and the wider scientific community. I have been a member and chair of UK and European
`Research Council Panels. All the committee positions have been either by invitation and/or election. I
`detail below only current committee roles or those recently held.
`
`1
`
`LUPIN EX 1054
`
`Page 1 of 27
`
`

`

`Furthermore, I have also shown scientific leadership in my role as Chief Scientist for the RPS, initiating
`the review of the RPS’s stance on homeopathy which resulted in myself giving evidence on behalf of the
`RPS at
`the Science and Technologies Select Committee’s Evidence Review in 2009
`(http://www.publications.parliament.uk/pa/cm200910/cmselect/cmsctech/45/45.pdf), initiating a review of
`Multi-compartment Compliance Aids MCAs) which resulted in a report published in 2013
`(http://www.rpharms.com/unsecure-support-resources/improving-patient-outcomes-through-the-better-
`use-of-mcas.asp), with has influenced on a national scale the use of MCAs and is quoted by NICE, the
`RPS
`being
`intimately
`involved
`in
`the
`campaign
`for
`clinical
`trial
`transparency
`(http://www.alltrials.net/supporters/organisations/rps-statement/) and, most recently, the development of
`the
`‘New
`Medicines,
`Better
`Medicines,
`Better
`Use
`of
`Medicines
`Guide’
`(http://www.rpharms.com/promoting-pharmacy-pdfs/nmbmbu---full-report.pdf) published May 2014.
`
`Current National Roles
`
`Core Member of Science and Technology Faculties Council Science Board
`http://www.stfc.ac.uk/696.aspx (2014-present)
`Science Board is the Science and Technology Facilities Council’s (STFC’s) principal scientific advisory
`committee, reporting directly to Council. Its purpose is to provide the STFC with a strategic scientific
`overview and assessment of, and science advice on, all of the programmes STFC supports. It is
`supported by advisory panels, peer review committees and other advisory committees.
`
`Facilities Forum (Committee Member 2013-present)
`The Faculties Forum is a new committee set up by The Institute of Physics to gather the views of users
`of National Central Facilities such as Diamond and ISIS to inform its policy work in dealing with the
`STFC, Research Councils UK (RCUK), etc. Committee membership is by invitation.
`
`Industrial Pharmacy Forum (http://www.rpharms.com/sector-groups/industrial-pharmacists-group.asp)
`(Committee Member 2011 - present)
`the Royal Pharmaceutical Society (RPS)
`The Industrial Pharmacy Forum (IPF) is a sub-group of
`representing the interests of industrial pharmacists both within the RPS and to the wider pharmaceutical
`arena. My role on the committee is particularly to promote the interests of the industrial pharmacists
`within the RPS.
`
`Member of the joint Institute of Physics and Royal Society of Chemistry UK Neutron Scattering
`Group
`Committee
`(http://www.iop.org/activity/groups/subject/ns/
`(Committee
`http://www.rsc.org/Membership/Networking/InterestGroups/NeutronScattering/index.asp)
`Member 2010-present)
`The UK Neutron Scattering Group (UKNSG) is a joint group of the Institute of Physics and the Royal
`Society of Chemistry which represents the interests of UK scientists using Neutron Central Facilities in
`the UK and Europe including organising meetings/conferences and responding to consultations on
`behalf of the community.
`
`Joint Pharmaceutical Analysis Group (http://www.jpag.org/) (Management Board Member 2007 -
`present)
`The Joint Pharmaceutical Analysis Group (JPAG) is a joint group of the Royal Pharmaceutical Society
`(RPS) and the Royal Society of Chemistry that exits to encourage, assist and extend the knowledge and
`study of pharmaceutical analysis and quality control, predominately by the holding of scientific meetings.
`My role on the management board is to promote the interests of JPAG within the RPS.
`
`Academic lead on a new small angle neutron scattering instrument (ZOOM) to be built on the
`new
`target
`station
`at
`the
`Rutherford
`Appleton
`Laboratories
`(http://ts-
`2.isis.rl.ac.uk/instruments/phase2/zoomWeb.pdf) (2006-present)
`I was invited by the Neutron Facility at Rutherford Appleton Laboratories (RAL), Didcot, Oxon, to be
`academic lead on a new small angle neutron scattering instrument (ZOOM). I twice had to present the
`scientific case for ZOOM, to the Scientific Advisory Committee prioritizing which new instruments should
`be built as well as presenting the case to the wider scientific community. ZOOM is one of
`the
`instruments being built in Phase Two of the New Target Station (known as TS2) at RAL.
`
`Organisation Committee of United Kingdom and Ireland Controlled Release Society
`(http://www.ukicrs.org/) (Organising Committee Member, 1999 - present; Treasurer 2006 - present)
`The United Kingdom and Ireland Controlled Release Society (UKICRS) is a very active Chapter of the
`Controlled Release Society - an International Society for delivery science and technology. I am a
`committee member and treasurer. The committee organizes research colloquia and conferences
`
`2
`
`Page 2 of 27
`
`

`

`including a 1-day UKICRS meeting, formerly held at the British Pharmaceutical Conference and now at
`PharmSci conference. The UKICRS committee has won the Controlled Release Society ‘Chapter of the
`Year’ in 2012 and 2013.
`
`Academy of Pharmaceutical Sciences (http://www.apsgb.org/) (Board Member 2003 - present, Vice -
`Chair 2011 - present)
`The Academy of Pharmaceutical Sciences (APS) is a professional body for pharmaceutical scientists in
`Great Britain, its objectives are to promote the pharmaceutical sciences. I am an elected member of the
`Board and am currently vice - chair.
`
`Recent National Roles
`
`Member of the Science and Technology Faculties Council’s Life Sciences & Soft Materials
`Advisory Panel (http://www.stfc.ac.uk/702.aspx) (Panel Member 2012-2014)
`New committee set up to report to Science board of the Science and Technology Faculties Council
`(STFC). Committee membership is by nomination.
`
`the Science and Technology Faculties Council’s Neutron Advisory Panel
`Member of
`(http://www.stfc.ac.uk/About+STFC/6009.aspx) (Panel Member 2009-2011)
`Standing committee of the Science and Technology Faculties Council (STFC) reporting to STFC’s
`Science Committee for Physical and Life Sciences on matters concerning neutron science, particularly
`its funding, in the UK.
`
`Engineering and Physical Sciences Research Council (EPSRC) Physical Sciences – Materials
`Review Panel (Panel member 2012)
`Member of materials review panel.
`
`Sub-panel 13(Pharmacy) for the 2008 Research Assessment Exercise (Member 2006-2008)
`One of a panel of 15 senior academics, selected for assessing research in UK Schools of Pharmacy.
`This was a very important role as it determined the level of research funding Schools within universities
`receive until the next comparable exercise in 2014.
`
`Member of the Science Advisory Panel for NIMROD (Panel Member 2006-2010)
`This panel reviews the scientific developments on the new neutron diffractometer called NIMROD being
`built at the Science and Technology Faculties Council’s Rutherford Appleton Laboratories. NIMROD was
`one of the instruments built in Phase One of the New Target Station (known as TS2) at RAL.
`
`Member of Laser Access Panel (Panel Member 2006-2009)
`This Council for the Central Laboratories of the Research Councils (CCLRC) (now the Science and
`Technology Faculties Council) committee was responsible for allocating laser time on the basis of
`applications submitted. It was a UK Research Council committee.
`
`Chairman of the Facility Access Panel 3: Large Scale Structures (Chairman 2004-2007)
`Chair of
`the Facility Access Panel (FAP) 3: Large Scale Structures. This committee was a grant
`awarding committee of the Council for the Central Laboratories of the Research Councils (CCLRC, now
`STFC) and was responsible for allocating ~ 360 days of neutron beam time per year, each day worth ~
`£20K (total budget ~ £7.5M).
`
`College
`Review
`Peer
`Council
`Research
`Sciences
`Physical
`and
`Engineering
`(http://www.epsrc.ac.uk/funding/apprev/college/Pages/default.aspx) (College Member, 2003-2005, 2006-
`2008, 2009-2013)
`College members are nominated experts who are called upon to assess research grant proposals
`submitted to Engineering and Physical Sciences Research Council (EPSRC) and draw up a ranked
`order list of research projects from submitted proposals.
`
`Current and Recent European and International Roles
`
`Formulation and Pharmaceutical Technology Special
`Pharmaceutical Federation
`http://www.fip.org/Formulation_Design_and_Pharmaceutical_Technology (Vice-chair 2011-present)
`This is a new Special Interest Group (SIG) set-up by the International Pharmaceutical Federation (FIP)
`to promote pharmaceutical science. The SIG will develop a programme of formulation-related activities
`
`Interest Group of
`
`the International
`
`3
`
`Page 3 of 27
`
`

`

`it will offer opportunities for networking, and
`In addition,
`at scientific meetings and workshops.
`professional development, including continuing education. I will become chair of the group in 2016.
`
`Neutron Instrument Review Panel of the Institute Laue Langevin, Grenoble, France (Member
`2011)
`Panel consisted of senior experts in the field of neutron science who were asked to review the suite of
`neutron instruments currently available at the Institute Laue Langevin (ILL) and to draw up priorities for
`these and other new instruments over the next 20 years.
`
`Assessment of the Pharmacy Department at the University of Brisbane, Queensland (2008)
`I was part of an international panel assessing the quality of the teaching and research in the Pharmacy
`Department at the University of Brisbane, Queensland.
`
`European Medicines Agency (Member 2008-2009)
`Member of an ad-hoc committee that produced an EU Reflection Paper entitled “Micellar Injectables”.
`
`Beam Time Scheduling Panel College 8 (Biological Science) of the Institute Laue Langevin,
`Grenoble, France (Member, 2006-2009)
`This committee is responsible for allocating neutron beam time on the basis of applications submitted.
`Institute Laue Langevin (ILL) is a European facility funded by a tripartite agreement between France,
`Germany and the UK (http://www.ill.fr/). This involved attending two meetings a year and reading about
`30 neutron beam time proposals at each meeting.
`
`SCIENCE ADVOCACY
`
`Media Work
`
`I have participated in a considerable amount of media work in my role as Chief Scientist at the Royal
`Pharmaceutical Society, and to a lesser extent in my academic position at King’s College London,
`examples of which are detailed below. I have developed a reputation as the media spokesperson for
`pharmaceutical science matters. To support these activities I have undertaken several media training
`course (including advanced training courses).
`
`Television
`I have been interviewed live as well as being pre-recorded for a number of National TV programmes
`including BBC 1 Breakfast (new herbal regulations (live), 2011), BBC 2 Newsnight (homeopathy, 2011),
`BBC News 24 (4 pieces - homeopathy (live), 2011; AstraZeneca closures (live), 2013; generic/branded
`antihistamines (2014); antibiotics (live), 2014), BBC Politics (science, 2014), BBC World News
`(antibiotics (live), 2014), BBC Watch Dog (generic and branded medicines 2012), BBC 2 Test House (2
`pieces - branded/generic and vitamins 2014), BBC 4 Pain, Poison and Pus (arsenic act 2013), ITN News
`(2 pieces - counterfeits, 2010; antibiotics, 2014), Skye News (4 pieces - antibiotics (live), 2013;
`antibiotics (pre-record and live) 2014; antibiotics (pre-record) 2015), Channel 4 Dispatches (anti-ageing
`creams, 2008), Channel 5 News (2 pieces - homeopathy 2012 (live); antibiotics (live), 2014). I have
`appeared on BBC Local TV (Look North) talking about the dangers of fat burners (2015). On the
`International front I was interviewed by Korean TV about the ‘New Medicines Guide’ (2014). I have also
`provided pharmaceutical advice for a range of programmes including a BBC 1 prime time programme
`(health benefits of bottled water, 2011), BBC1 Trust Me I Am A Doctor (generics/branded, 2014). I have
`recently acted as a consultant on for a BBC1 commissioned science documentary entitled ‘The Truth
`About Your Medicine Cabinet’, shown 2015.
`
`Radio
`I have been interviewed live as well as being pre-recorded for a large number of Local and National
`programmes including BBC local radio on the use of placebo’s in children, Radio 4 on the (lack of a)
`scientific basis for homeopathy and the advantageous/disadvantageous of
`the recent EU Herbal
`Regulations (comments which were syndicated throughout the BBC radio network), BBC 5 Live on the
`discovery of antibiotics, multiple BBC Local radio stations on the danger of rapid withdrawal of
`antidepressant medication, BBC local radio on the use of microneedles, BBC Solent on branded and
`generic medicines, BBC Oxford and Drive Time on homeopathy, multiple BBC Local radio stations on
`the dangers of fat burners (2015). Last year (2014) I was interviewed twice live by John Humphries on
`BBC R4’s Today programme, live on BBC Radio Scotland, pre-recorded on Voice of Russia and Radio
`Sheffield about antibiotic resistance and live on BBC R4’s You and Yours about personalized medicine.
`
`4
`
`Page 4 of 27
`
`

`

`Press
`I have worked with Sense about Science (http://www.senseaboutscience.org/) to give a statement about
`the dangers of using homeopathic nosodes instead of anitmalarials when travelling to endemic areas.
`Over recent years I have been interviewed by a number of National newspapers including the Daily
`Express, the Daily Mail, the Times, the Metro and the Big Issue on a wide range of pharmaceutical
`issues including generic and branded medicines, herbal medicines, prescribing medicines by brand
`name, how medicines work, biosimilars. Last year (214) I also commented on the potential merger of the
`two large Pharma companies, Pfizer and AstraZeneca in the Times.
`
`On-line Media
`I have been interviewed by a range of on-line TV stations and newspapers including BBC on-line on the
`use of placebo’s in children (2008) matter of re-purposing of medicines (2013), the difference between
`branded and generic (2013) and the RPS New Medicines Guide (2014) and MotherBoard (2014) also
`about the New Medicines Guide. I feature in a series of short vignettes on the HealthVista web-site about
`over the counter medicines including generic and branded medicines, from the mind to the counter.
`Homeopathy, painkillers and the placebo effect. I have appeared in a short Royal Pharmaceutical
`Science video (available on the internet) describing ‘how medicines are made’
`(2012)
`(https://www.youtube.com/watch?v=SKGTcmPCH1o).
`
`Media Presentations
`I have presented to the media at special media only events on the subject of personalised medicine
`(2013) and antibiotics (2014).
`
`Response to Public Consultations
`
`I have given written and oral evidence at a Science and Technology Select Committee of the UK
`Government’s Evidence Session into the (lack of) scientific and clinical evidence to support the use of
`homeopathy (2009). I have also provided written evidence to a wide variety of consultations including
`(but not exclusively)
`those of
`the Medicines Health Regulatory Authority (MHRA), The General
`Pharmaceutical Council
`(GPhC) and the Border Control Agency,
`the Faculty of Pharmaceutical
`Medicine, the World Health Organization (WHO) and the National Institute for Health and Care Excellent
`(NICE).
`
`Round Table Discussions
`I have attended the round table discussion entitled ‘fixing the broken business model in antimicrobial
`resistance’ (AMR) (2014) organized by PricewaterhouseCoopers, Gordon Museum, King’s College
`London. I attended (invitation only) the Foundation for Science and Technology meeting on antimicrobial
`resistance held at the Royal Society (2014).
`
`PUBLIC ENGAGEMENT
`
`I am very keen to promote science to all ages of the public and have been involved in a number of public
`engagement initiatives including
`
`Lecture entitled ‘what is a medicine?’ given to Ashford, Middlesex, Mothers Union.
`
`School talk for 6th form students entitled ‘The making and taking of medicines, the past, present and
`future’ given in conjunction with Briony Hudson, Keeper of the Museum, RPS.
`
`Lecture on ‘Personalized medicine – what is it?’ as part of schools debate in conjunction with the
`Economic and Social Research Council, the English Debating Union and the Royal Pharmaceutical
`Society (2009 and 2010).
`
`I have organized and participated in Science Cafés on the subjects of ‘Personalized medicine’ (2012),
`‘Performance enhancing drugs’ (2013) and ‘Clean water’ (2014).
`
`Supervised young people wishing to gain experience of working in a research environment before going
`on to 6th form (2012 and 2014).
`
`5
`
`Page 5 of 27
`
`

`

`School talks to year 11 Religious Studies students on ‘Medicines use in sport’ and ‘Personalised
`medicine’ (2013).
`
`I have also provided comment on potential of 3-D printing for production of medicines to the Science
`‘The
`Future
`of
`Medicine’
`Museum
`for
`their
`2013
`exhibition
`(http://www.sciencemuseum.org.uk/~/media/Documents/visit_us/antenna/3D%20Printing%20the%20Fut
`ure%20of%20Medicine.pdf).
`
`Lecture entitled ‘Drugs, genes and ethics’ Reach Out for Healthcare Science Summer School for 14-15
`year olds, King’s Health Partners and Health Education England (2014).
`
`Participated in the debate entitled ‘Should medicine be more about me?’ Times Cheltenham Science
`Festival (2014) (http://www.cheltenhamfestivals.com/science/whats-on/2014/should-medicine-be-more-
`about-me/).
`
`the Scottish Parliament
`in
`resistance
`antimicrobial
`about
`event
`a
`at
`Spoke
`(http://www.pharmaceutical-journal.com/your-rps/rps-antimicrobial-resistance-event-prompts-
`parliamentary-debate/20067246.article?adfesuccess=1).
`
`(2014)
`
`Participated in a public debate entitled ‘Will the global need for antibiotics outpace that for profit
`margins?’
`North
`West
`Biotech
`Initiative,
`Manchester
`University
`(2014)
`(https://mec.portals.mbs.ac.uk/Newsevents/Enterprisenews/tabid/112/ArticleID/149/ArtMID/510/PgrID/51
`0/PageID/5/Will-the-Global-Need-for-Antibiotics-Outpace-that-for-Profit-Margins.aspx).
`
`Participated in a debate entitled ‘The drugs don’t work: London without antibiotics’ for the 2015 for
`British Science Week
`(http://www.britishscienceassociation.org/Event/the-drugs-dont-work-london-
`without-antibiotics).
`
`I gave a talk at the 2015 Cambridge Science Festival entitled ‘Homeopathy – science fact of science
`fiction?’ (https://www.soci.org/Events/Display-Event?EventCode=SCGE190315).
`
`SUPPORT OF WOMEN AND SCIENCE
`
`I am keen on ensuring that woman have equal opportunities in science as men do to ensure the most
`effective utilization of the work force. Below are a number of recent initiatives I have been involved in.
`
`I recorded a short video (available on the internet) on women in science (for Ada Lovelace day, 2013)
`(https://www.youtube.com/watch?v=B4QVzCU7MHQ).
`
`Featured in the Pharmaceutical Journal article (2013) entitled ‘Celebrating the work of women in
`science’ for Ada Lovelace Day.
`
`Organised the first Woman in HealthCare Leadership Symposium (2014) Royal Pharmaceutical
`Society and Academy of Pharmaceutical Sciences, London. The second meeting to be run October
`2015. The inaugural meeting was so successful that it is now anticipated that these meetings will be run
`on an annual basis.
`
`Featured as 1 of 6 woman in the Pharmaceutical Journal article (2014) entitled ‘Woman inspiring
`change in pharmacy’.
`
`I act as a reviewer for Athena Swan applications (2015).
`
`Inspirational speaker at a Springboard Woman’s Development Day (2015) held at King’s College
`London.
`
`ACADEMIC AND OTHER LEADERSHIP
`
`Administration within KCL
`
`Head of the Pharmaceutical Biophysics Research Group (2002-present)
`
`6
`
`Page 6 of 27
`
`

`

`I have line-management responsibility for 6 full time academic staff, plus several emeritus staff,
`associated post-doctoral fellow and PhD students.
`
`Member of Institute of Pharmaceutical Sciences Executive (2002-2013)
`As Head of the Pharmaceutical Biophysics Group, I have been a member of the executive committee
`(i.e. governing body) of the Institute of Pharmaceutical Science. The executive, which meets monthly
`and comprises of
`the heads of
`research groups,
`is responsible for overseeing the institute's
`governance, research strategy and policy, including horizon scanning for funding opportunities, PhD
`student management and health and safety.
`
`Member of Joint Institute of Pharmaceutical Sciences/Clinical Academic Group Executive
`(2013-present)
`I am a member of the merged Institute of Pharmaceutical Science/Clinical Academic Group executive.
`
`Teaching Roles within KCL
`
`I have wide ranging teaching and lecturing experience, both at the undergraduate and postgraduate level
`within King's College London and in particular the Institute of Pharmaceutical Science. My teaching
`includes membranes and drug transport; surface and interfacial phenomena; physical chemistry of
`micelles; physical chemistry of emulsions; surfactant systems; particulates as drug delivery vehicles;
`biopharmaceutics and bio-pharmacy, gastrointestinal drug absorption;
`transdermal drug delivery,
`evidence-based medicine; gene delivery. Since taking up my half time role at the RPS I have less
`contact time with the undergraduate and postgraduate taught students, and currently no major teaching
`administrative role. I am still involved, however, in course development and was one of a small team
`who lead the recent successful accreditation by the General Pharmaceutical Council for the Pharmacy
`course at King’s College London. I also give lectures to final year students on a variety of subjects
`including evidence based medicine and gene delivery.
`
`Course Development within KCL
`
`I am an innovative teacher, who has introduced a variety of new teaching methods, such as problem-
`based learning, to the Pharmacy Course as well as initiating new schemes such as the skills-based topic
`weeks – weeks in which all
`lectures and practical’s were suspended and the students focused on
`particular transferable skills such as science communication and statistical analysis.
`
`I have recently been involved in developing a series of 4th year student debates on “real-life” science into
`practice dilemmas which was a finalist
`in a National Education Prize (Times Higher Education
`Supplement) and won the KCL award for innovative teaching in 2011. The student debates have been
`so successful that they are now being rolled out to include other UK Schools of Pharmacy.
`
`Other course design, development and implementation includes a series of novel practical classes for
`MPharm undergraduate degree, including the MPharm (III) Formulation Optimization practical course in
`which small groups of students are given a formulation to prepare using optimization techniques and
`under as near industrial development laboratory conditions as possible. This innovative course has
`subsequently been copied by at least one other School of Pharmacy.
`
`In 2000, I initiated a major review of the undergraduate MPharm course, which resulted in a complete re-
`write of our undergraduate course to run in cross-discipline therapeutic streams. This review was
`achieved by running a series of one day workshops in which all staff participated. The result of which
`was that KCL was the first UK Pharmacy School
`to teach across the traditional streams of
`pharmaceutical chemistry, pharmaceutics, pharmaceutical biology and pharmacy practice. I was one of
`a team of four that lead and coordinated this major re-write of the undergraduate MPharm course. The
`concept of our course has now been copied by several other UK Schools of Pharmacy.
`
`Other Teaching Roles
`
`I have been an invited lecturer on external University courses including the 4th year Drug Delivery
`Elective on the MPharm degree and the MSc in Drug Delivery at the School of Pharmacy, Brunswick
`Square, University of London, the final year Pharmacy undergraduate course at Damascus University,
`Syria and the International MSc in Pharmaceutical Technology, Chulalongkorn University, Bangkok,
`Thailand (biannually for the past 14 years). Invited lecturer on teaching methodology courses (eg the
`teaching of basic mathematics to pharmacy undergraduates) run by the Academic Pharmacy Group of
`
`7
`
`Page 7 of 27
`
`

`

`the Royal Pharmaceutical Society of Great Britain for University lecturers. I also teach (lecture and
`tutorials) on the biannual Oxford School of Neutron Scattering (held at Oxford University).
`
`External examiner for other Pharmacy degree courses in the UK including: Liverpool John Moores
`University (2001-2005); University of Central Lancashire (2007-2011); University of Belfast (2009-
`2012); University of Strathclyde (2013-to date).
`
`Other Course Development
`
`I was advisor on the development of the new Pharmaceutical Technology course of the Pharmacy
`Degree at
`the new Sekem School of Pharmacy, Egypt (2007-8).
`I also acted as reviewer of
`the
`Pharmacy Courses at Reading University (2013) and Strathclyde (2013) prior to their reaccreditation visit
`by the General Pharmaceutical Council. I was involved with the course review of Brighton Pharmacy
`Department (2013).
`
`RESEARCH
`
`Experienced researcher, publishing in high impact journals in the fields of physical/colloid chemistry,
`pharmaceutical science and nanomedicine. Pioneered (with Dr DJ Barlow, KCL) the use of neutron
`scattering techniques to aid the understanding and the improved design of drug and gene delivery
`systems. Before then, with the exception of neutron crystallography, neutron scattering was not used in
`the pharmaceutical science community. As recognition of my research expertise I was awarded in 2009
`a Fellowship of the RPS for Distinction in the Science of Pharmacy (less than 1% of the membership are
`awarded Fellowships) and an Eminent Fellowship of the Academy of Pharmaceutical Sciences (currently
`there are only 19 such Eminent Fellows).
`
`Successful at obtaining UK Research Council (including BBSRC, EPSRC and NERC) and Charity
`(Leverhulme Trust, Maplethorpe Trust) money for fundamental research studies. Significant long-term
`on-going
`collaborations
`between
`several Pharmaceutical Companies, most
`notably with
`GlaxoSmithKline and AstraZeneca who have provided funding for both fundamental and applied
`research.Several long term, very successful research collaborations with academics both within King’s
`(Dr BJ Barlow (> 60) and Dr CD Lorenz85,87,95,104,114,116 and within other Universities (eg Professor HC
`Hailes & Dr AB Tabor41,58,74,77,94,103,119, Department of Chemistry, University College London, London, Dr
`SE McLain85,95,104,114,116, Department of Biochemistry, University of Oxford), UK Research Institutions
`(e.g. Drs R Heenan37,40,51,53,93,98,111, AV Hughes69,78,96,100,112 and SM King83,110,117, Rutherford Appleton
`Laboratories, Didcot) and overseas Research Institutions (e.g. Dr G Fragneto,55,80,81,101,107 and Dr R
`Campbell96,100 Institute Laue Langevin, Grenoble, France, Dr B Boyd84, Monash University, Melbourne,
`Australia, Professor F Szoka92, UCSF, California, USA, Professor J Bouwstra90,109,120, University of
`Leiden, Holland). Invited speaker at many National and International Conferences.
`
`Successfully supervised 36 research students (all of whom were successful and submitted within 4 years
`of registration). 4 of my former PhD students have taken up academic posts in the UK, with a further 4
`taking up academic positions abroad. Over half of the 21 undergraduate vacation project students I have
`supervised have subsequently gone on to undertake postgraduate research studies. Similarly almost half
`of the MSc project students that I have supervised (ie 13 out of a total of 30) have gained a distinction
`and/or gone on to study for a PhD, many with myself as supervisor. I was awarded a KCL Graduate
`School Supervisory Excellence Award in 2012.
`
`Research highlights have been published in the scientific press/literature e.g. our recent work on the fate
`of nanoparticles in the environment received considerable media coverage as did our research on the
`mechanism of action of the antifungal drug, amphotericin B.
`
`Research Grants
`
`Research Council, Charity and Industrial Grants
`
`Between 1987 and 2005, 48 grants totaling in excess of £3,500,000 were obtained (neutron beam time
`awarded directly via the facility is not included in this total, see below for details of these awards). Of
`these 48 grants awarded prior to 2006, I was sole or principal applicant on 36. The grants were
`principally obtained from Research Councils, Charities and the British Pharmaceutical Industry. Only
`
`8
`
`Page 8 of 27
`
`

`

`grants obtained since 2005 are listed below. Since 2005 over £2,200,000 (excluding neutron time, see
`below) of grant funding has been awarded.
`
`Deuteration initiative for neutron scattering and NMR studies of biological molecules
`2006-2008; £691,468. Standard EPSRC grant Joint with T Forsyth (Principal investigator, Keele) and
`others
`
`Smart polymeric materials: pH responsive polymers as vectors for gene delivery
`2007-2009; £80,000. CW Maplethorpe Fellowship for JK Lam. MJ Lawrence (Principal Investigator)
`
`Pharmaceutical and cosmetic silica nanoparticles: towards an understanding of their structure,
`fate and behaviour in aquatic systems
`2007-2008; £63,880 NERC Environmental Nanoscience Initiative MJ Lawrence (Principal investigator)
`and HP Jarive, SM King
`
`Development of new injectable, PolyGeneCaP composites for gene therapy
`2008-2010; £25,186 EPSRC Responsive mode grant MJ Lawrence (Principal investigator)
`
`Biophysical studies of model bio-membranes & investigation of the molecular mechanism of the
`anti-mycotic drug, amphotericin
`2007-2011; £148,804 EPSRC Next Generation User Facility Panel Joint with DJ Barlow (Principal
`investigator) and AF Drake
`
`Mitchondrial gene delivery
`2008-2012; £50,000 King’s College Studentship Joint with DJ Barlow (Principal investigator)
`
`Molecular mechanisms of antimicrobial peptides: phase changes induced in endotoxic bacterial
`lipopolysaccharide
`2009-2013; £204,302 EPSRC Next Generation User Facility Panel 2008 Joint with RD Harvey (Principal
`investigator), DJ Barlow and AJ Mason
`
`Nanoparticles for the targeted delivery of therapeutic agents to the brain for the treatment of
`dementias
`2009-2012; £341,212 EPSRC Nanotechnology Grand Challenges Healthcare MJ Lawrence (Principal
`investigator)
`
`Protein-containing phospholi